Noraylis Lorenzo

Characterization of two experimental rodent models for evaluating novel drugs for rheumatoid arthritis

G. Padrón, V. Morera, Ariadna Hernández, 2008 .

APL-1, an altered peptide ligand derived from human heat-shock protein 60, selectively induces apoptosis in activated CD4+ CD25+ T cells from peripheral blood of rheumatoid arthritis patients.

W. van Eden, R. van der Zee, F. Broere, 2013, International immunopharmacology.

Development and validation of a bioanalytical method based on LC–MS/MS analysis for the quantitation of CIGB‐814 peptide in plasma from Rheumatoid Arthritis patients

V. Besada, L. González, Y. Ramos, 2017, Journal of pharmaceutical and biomedical analysis.

An altered peptide ligand corresponding to a novel epitope from heat-shock protein 60 induces regulatory T cells and suppresses pathogenic response in an animal model of adjuvant-induced arthritis

D. Klatzmann, G. Padrón, M. V. Hernández, 2011, Autoimmunity.

Current treatment of rheumatoid arthritis . Perspectives for the development of antigen-specific therapies

A. Barberá, N. Lorenzo, Noraylis Lorenzo, 2012 .

APL1, an altered peptide ligand derived from human heat-shock protein 60, increases the frequency of Tregs and its suppressive capacity against antigen responding effector CD4 + T cells from rheumatoid arthritis patients

F. Broere, G. Padrón, W. Eden, 2016, Cell Stress and Chaperones.

Suppression of the pathogenic responses in an animal model of adjuvant-induced arthritis by a peptide corresponding to a novel epitope from heat-shock protein 60

G. Padrón, Nelia López, N. Merino, 2008 .

An altered peptide ligand corresponding to a novel epitope from heat-shock protein 60 induces regulatory T cells and suppresses pathogenic response in an animal model of adjuvant-induced arthritis

D. Klatzmann, G. Padrón, A. Torres, 2011, Autoimmunity.